• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Silk Road Medical Reports Third Quarter 2023 Financial Results

    11/8/23 4:05:00 PM ET
    $SILK
    Medical/Dental Instruments
    Health Care
    Get the next $SILK alert in real time by email

    SUNNYVALE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended September 30, 2023.

    "As announced on November 2, we are thrilled to welcome Chas McKhann as the new Chief Executive Officer of Silk Road Medical," said Jack Lasersohn, Chairman of the Board of Directors. "Chas is a skilled and experienced leader with a track record of effectively building and scaling medical device businesses into underpenetrated markets. We believe he is the right leader to leverage our strong infrastructure, skilled commercial team, and substantial body of clinical evidence to drive further TCAR adoption."

    Third Quarter 2023 Financial Results

    Revenue for the third quarter of 2023 was $44.4 million, an increase of $7.1 million or 19%, compared to the third quarter of 2022. Growth was driven primarily by increased TCAR adoption.

    Gross profit for the third quarter of 2023 was $32.4 million compared to $28.1 million for the third quarter of 2022. Gross margin was 73% for the third quarter of 2023 compared to 75% for the third quarter of 2022. The decrease was driven by a revaluation of standard costs in the prior year period which benefitted margins, as well as higher manufacturing costs associated with having two manufacturing facilities fully operational in the third quarter of 2023.

    Operating expenses were $46.1 million for the third quarter of 2023, compared to $37.3 million in the comparable prior year period, which represents an increase of 24%. The increase was due primarily to the continued expansion of the sales team and commercial efforts.

    Net loss was $12.8 million in the third quarter of 2023, or $0.33 per share, as compared to a loss of $10.3 million, or $0.29 per share, in the corresponding period of the prior year.

    Cash, cash equivalents and investments were $197.2 million as of September 30, 2023.

    2023 Financial Guidance

    Silk Road Medical projects revenue for full year 2023 to range from $170 million to $174 million, which represents 23% to 26% growth over the Company's prior year revenue.

    Conference Call

    Silk Road Medical will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, November 8, 2023, to discuss its third quarter 2023 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the webcast will be available at https://investors.silkroadmed.com.

    About Silk Road Medical

    Silk Road Medical, Inc. (NASDAQ:SILK), is a medical device company located in Sunnyvale, California, and Plymouth, Minnesota, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook.

    Forward-Looking Statements

    Statements contained in this release that relate to future, not past, events are forward-looking statements under the Private Securities Litigation Reform Act of 1995, including Silk Road Medical's financial guidance. Forward-looking statements are based on current expectations of future events and often can be identified by words such as "expect," "should," "project," "anticipate," "intend," "will," "can," "may," "believe," "could," "continue," "outlook," "guidance," "future," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Risks and uncertainties may cause Silk Road Medical's actual results to be materially different than those expressed in or implied by Silk Road Medical's forward-looking statements. For Silk Road Medical, such risks and uncertainties include, among others, future operating results and financial performance; risks surrounding the CEO transition; the Company's success in retaining and recruiting key personnel; the ability to continue to grow the business and expand the use of TCAR; the ability to obtain an adequate supply of materials and components from its third-party suppliers; product development plans and the ability to commercialize new products in a timely manner; the success of current clinical trials; plans to conduct further clinical trials; the ability to obtain additional indications or new regulatory approvals or clearances for its products; market acceptance and use of its products by physicians; the ability to grow and leverage its commercialization infrastructure; increased competition; the effect of economic conditions and COVID-19 or similar pandemics on its business; government and third-party payer coverage and reimbursement and the ability to obtain and maintain intellectual property protection for its products. More detailed information on these and other factors that could affect Silk Road Medical's actual results are described in its filings with the U.S. Securities and Exchange Commission, including its quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023. Silk Road Medical undertakes no obligation to update its forward-looking statements.

    Investor Contact:

    Marissa Bych

    Gilmartin Group LLC

    [email protected]

    Media:

    Michael Fanucchi

    Silk Road Medical

    [email protected]

    SILK ROAD MEDICAL, INC.
    Statements of Operations Data
    (unaudited, in thousands, except share and per share data)
                
     Three Months Ended Nine Months Ended
     September 30, September 30,
     2023 2022 2023 2022
    Revenue$44,435  $37,374  $129,864  $98,567 
    Cost of goods sold 12,050   9,308   37,580   26,897 
    Gross profit 32,385   28,066   92,284   71,670 
    Operating expenses:           
    Research and development 10,047   8,471   31,260   27,249 
    Selling, general and administrative 36,009   28,821   105,923   83,795 
    Total operating expenses 46,056   37,292   137,183   111,044 
    Loss from operations (13,671)  (9,226)  (44,899)  (39,374)
    Interest income 2,617   617   7,339   751 
    Interest expense (1,732)  (1,714)  (5,137)  (3,366)
    Loss on debt extinguishment —   —   —   (245)
    Other income (expense), net (2)  4   (35)  (162)
    Net loss (12,788)  (10,319)  (42,732)  (42,396)
    Other comprehensive loss:           
    Unrealized gain (loss) on investments, net 47   (189)  (118)  (191)
    Other comprehensive loss 47   (189)  (118)  (191)
                
    Net loss and comprehensive loss$(12,741) $(10,508) $(42,850) $(42,587)
                
    Net loss per share, basic and diluted$(0.33) $(0.29) $(1.10) $(1.21)
                
    Weighted average common shares used to compute net loss per share, basic and diluted 38,865,011   35,303,958   38,722,012   35,157,840 
                    



    SILK ROAD MEDICAL, INC.
    Balance Sheets Data
    (unaudited, in thousands)
          
     September 30, 2023 December 31, 2022
    Assets     
    Current assets     
    Cash and cash equivalents$29,188  $55,358 
    Short-term investments 163,673   158,316 
    Accounts receivable, net 21,779   18,007 
    Inventories 22,066   19,293 
    Prepaid expenses and other current assets 4,277   3,924 
    Total current assets 240,983   254,898 
    Long-term investments 4,348   — 
    Property and equipment, net 8,337   9,372 
    Restricted cash —   155 
    Other non-current assets 7,196   5,260 
    Total assets$260,864  $269,685 
    Liabilities and stockholders' equity     
    Current liabilities     
    Accounts payable$5,094  $2,523 
    Accrued liabilities 18,928   21,965 
    Total current liabilities 24,022   24,488 
    Long-term debt 75,364   74,596 
    Other liabilities 8,336   6,726 
    Total liabilities 107,722   105,810 
    Stockholders' equity     
    Preferred stock, $0.001 par value —   — 
    Common stock, $0.001 par value 39   38 
    Additional paid-in capital 539,831   507,715 
    Accumulated other comprehensive loss (284)  (166)
    Accumulated deficit (386,444)  (343,712)
    Total stockholders' equity 153,142   163,875 
    Total liabilities and stockholders' equity$260,864  $269,685 
            


    Primary Logo

    Get the next $SILK alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SILK

    DatePrice TargetRatingAnalyst
    7/11/2024Buy → Sell
    Argus
    3/7/2024$24.00Hold → Buy
    Argus
    1/19/2024$9.00 → $20.00Hold → Buy
    Stifel
    1/3/2024$20.00Buy
    Lake Street
    10/24/2023Underperform → Peer Perform
    Wolfe Research
    10/11/2023$54.00 → $14.00Buy → Neutral
    B. Riley Securities
    10/11/2023Buy → Neutral
    CL King
    10/11/2023$45.00 → $12.00Buy → Hold
    Stifel
    More analyst ratings

    $SILK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Zurbay Donald returned 12,610 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Silk Road Medical Inc (0001397702) (Issuer)

      9/18/24 9:12:36 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Director Weatherman Elizabeth H returned 155,004 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Silk Road Medical Inc (0001397702) (Issuer)

      9/18/24 9:08:24 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Director Lasersohn Jack W returned 16,735 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Silk Road Medical Inc (0001397702) (Issuer)

      9/18/24 9:01:12 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ballinger Kevin J. bought $198,783 worth of shares (11,700 units at $16.99), increasing direct ownership by 192% to 17,807 units (SEC Form 4)

      4 - Silk Road Medical Inc (0001397702) (Issuer)

      3/7/24 6:01:30 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Boston Scientific Announces Results for Third Quarter 2024

      MARLBOROUGH, Mass., Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared to $505 million or $0.34 per share a year ago, and achieved adjusted3 EPS of $0.63 for the period, compared to $0.50 a year ago.

      10/23/24 6:30:00 AM ET
      $BSX
      $SILK
      Medical/Dental Instruments
      Health Care
    • Boston Scientific Closes Acquisition of Silk Road Medical, Inc.

      MARLBOROUGH, Mass., Sept. 17, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Silk Road Medical, Inc. (NASDAQ:SILK), a medical device company that pioneered a new approach for stroke prevention and the treatment of carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR). "Completing this acquisition enables Boston Scientific to strengthen our vascular technology solutions by bringing the innovative TCAR platform to a greater number of physicians and their pa

      9/17/24 8:31:00 AM ET
      $BSX
      $SILK
      Medical/Dental Instruments
      Health Care
    • SILK Alert: Monsey Firm of Wohl & Fruchter Renews Investigation of the Proposed Sale of Silk Road Medical to Boston Scientific

      MONSEY, N.Y., Aug. 19, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP has renewed its investigation into the fairness of the proposed sale of Silk Road Medical, Inc. (NASDAQ:SILK) ("SILK") to Boston Scientific Corporation for $27.50 per share in cash. On July 29, 2024, SILK filed a definitive proxy concerning the proposed sale with the SEC. Based on our review of the proxy, we have renewed our investigation into whether there are any undisclosed potential conflicts of interest. If you remain a SILK shareholder and question the fairness of the price or have any other concerns, you may contact our firm at the following link to discuss your legal rights at no charge: https:/

      8/19/24 9:31:00 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    SEC Filings

    See more
    • SEC Form 15-12G filed by Silk Road Medical Inc.

      15-12G - Silk Road Medical Inc (0001397702) (Filer)

      9/27/24 4:00:39 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Silk Road Medical Inc.

      EFFECT - Silk Road Medical Inc (0001397702) (Filer)

      9/24/24 12:15:03 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • SEC Form 25-NSE filed by Silk Road Medical Inc.

      25-NSE - Silk Road Medical Inc (0001397702) (Subject)

      9/17/24 9:33:30 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Silk Road Medical downgraded by Argus

      Argus downgraded Silk Road Medical from Buy to Sell

      7/11/24 7:47:06 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Silk Road Medical upgraded by Argus with a new price target

      Argus upgraded Silk Road Medical from Hold to Buy and set a new price target of $24.00

      3/7/24 7:36:37 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Silk Road Medical upgraded by Stifel with a new price target

      Stifel upgraded Silk Road Medical from Hold to Buy and set a new price target of $20.00 from $9.00 previously

      1/19/24 8:14:13 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Silk Road Medical Inc.

      SC 13D/A - Silk Road Medical Inc (0001397702) (Subject)

      9/19/24 8:16:37 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by Silk Road Medical Inc.

      SC 13D - Silk Road Medical Inc (0001397702) (Subject)

      8/12/24 4:21:48 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Silk Road Medical Inc.

      SC 13G/A - Silk Road Medical Inc (0001397702) (Subject)

      7/10/24 1:45:37 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Financials

    Live finance-specific insights

    See more
    • Boston Scientific Announces Results for Third Quarter 2024

      MARLBOROUGH, Mass., Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational1 basis and 18.2 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared to $505 million or $0.34 per share a year ago, and achieved adjusted3 EPS of $0.63 for the period, compared to $0.50 a year ago.

      10/23/24 6:30:00 AM ET
      $BSX
      $SILK
      Medical/Dental Instruments
      Health Care
    • Boston Scientific Announces Results for Second Quarter 2024

      MARLBOROUGH, Mass., July 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent on a reported basis, 16.1 percent on an operational1 basis and 14.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $324 million or $0.22 per share (EPS), compared to $261 million or $0.18 per share a year ago, and achieved adjusted3 EPS of $0.62 for the period, compared to $0.53 a year ago.

      7/24/24 6:30:00 AM ET
      $BSX
      $SILK
      Medical/Dental Instruments
      Health Care
    • Silk Road Medical Reports First Quarter 2024 Financial Results

      SUNNYVALE, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended March 31, 2024. "Our team delivered a strong start to 2024 as we deepened relationships with the physicians we serve and continued broadening our patient impact," said Chas McKhann, CEO of Silk Road Medical. "In the first quarter, we made meaningful commercial progress while also taking steps toward sustainable profitability. We enter the second quarter feeling energized by TCAR's outstanding value proposition for physicians and patients and in our opportun

      4/30/24 4:05:00 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care

    $SILK
    Leadership Updates

    Live Leadership Updates

    See more
    • Silk Road Medical Names Chas McKhann Chief Executive Officer

      SUNNYVALE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK) ("Silk Road" or the "Company"), a company focused on reducing the risk of stroke and its devastating impact, today announced that Chas McKhann has been appointed Chief Executive Officer (CEO), effective immediately. Mr. McKhann is an accomplished leader with more than 25 years of experience in the medical device industry, including C-suite positions at seven public and private companies. Most recently, Mr. McKhann served as President and CEO of Apollo Endosurgery (acquired by Boston Scientific in April 2023), where he created and led a transformational growth strategy for the company's minimal

      11/2/23 8:00:00 AM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Silk Road Medical Announces Retirement of CEO Erica Rogers

      Working with Leading Executive Search Firm to Identify Successor SUNNYVALE, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that CEO Erica Rogers plans to retire from the Company following the completion of a succession process. The Company is working with Spencer Stuart, a leading executive search firm. To ensure a smooth transition, Ms. Rogers will remain as President and CEO of the Company until her successor is appointed. "I'd like to thank Erica for her tremendous contributions to Silk Road over the last 11 years. Erica has been integral in leading and expand

      10/10/23 4:20:00 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care
    • Silk Road Medical Names Dr. Tanisha Carino to Board of Directors

      SUNNYVALE, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (NASDAQ:SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that it has appointed Dr. Tanisha Carino to its Board of Directors. Tanisha Carino, Ph.D., is a health policy expert bringing over 20 years of experience driving growth and impact across multiple healthcare leadership positions in the government, private, and non-profit sectors. She most recently served as Executive Vice President, Chief Corporate Affairs Officer of Alexion, a Fortune 500 biotechnology company focused on rare disease, which was recently acquired by AstraZeneca.   Prior to Alexion, she serv

      7/26/21 4:05:00 PM ET
      $SILK
      Medical/Dental Instruments
      Health Care